目的 分析乙型肝炎病毒（HBV）感染患者并发2型糖尿病（T2DM）相关风险因素。方法 研究收集2024年1月~2025年5月期间，于周口市传染病医院（周口市结核病防治所、周口市第五人民医院）接受治疗的HBV感染患者临床资料，共纳入患者95例，根据HBV感染后是否并发T2DM分组，合并T2DM患者纳入并发组（n=21），非合并T2DM患者纳入对照组（n=74），比较两组患者基线资料及实验室检查数据，逻辑回归分析HBV感染患者并发T2DM风险因素。结果 并发组年龄、体重指数（BMI）、甘油三酯（TG）高于对照组（P＜0.05），年龄≥45岁、BMI肥胖、HBV感染时间≥6个月、TG≥1.7mmol/L、吸烟、乙型肝炎表面抗原（HBsAg）阳性及纤维化-4（FIB-4）指数≥2.67例数占比高于对照组（P＜0.05）。年龄≥45岁[OR=21.599（95%CI：2.875-162.262）]、BMI（肥胖）[OR=16.729（95%CI：1.443-193.981）]、HBV感染时间≥6个月[OR=6.199（95%CI：1.101-34.904）]、吸烟[OR=9.429（95%CI：1.344-66.141）]、TG≥1.7mmol/L[OR=71.834（95%CI：7.060-730.897）]是HBV感染患者并发T2DM危险因素（P＜0.05）。结论 HBV感染患者并发T2DM受人口学特征年龄、BMI、临床病程HBV感染时间、共病血脂异常及生活方式吸烟的共同影响。

Abstract: Objective To analyze risk factors associated with the development of type 2 diabetes mellitus (T2DM) in patients with hepatitis B virus (HBV) infection. Methods Clinical data were collected from HBV-infected patients treated at the Zhoukou City Infectious Disease Hospital (Zhoukou City Tuberculosis Prevention and Control Institute)between January 2024 and May 2025. A total of 95 patients were included in the study, Patients were grouped based on the presence or absence of T2DM following HBV infection. Patients with T2DM were included in the T2DM group (n=21), while those without T2DM were included in the control group (n=74). Baseline characteristics and laboratory test data were compared between the two groups, and logistic regression analysis was performed to identify factors associated with the development of T2DM in HBV-infected patients. Results The age, body mass index (BMI), and triglycerides (TG) in the intervention group were higher than those in the control group (P < 0.05); The proportion of cases with age ≥45 years, obese BMI, HBV infection duration ≥6 months, TG ≥1.7 mmol/L, smoking, hepatitis B surface antigen (HBsAg) positivity, and a FIB-4 score ≥2.67 was higher than that in the control group (P < 0.05). Age ≥ 45 years [OR = 21.599 (95% CI: 2.875–162.262)], BMI (obesity) [OR = 16.729 (95% CI: 1.443–193.981)], duration of HBV infection ≥ 6 months [OR = 6.199 (95% CI: 1.101–34.904)], smoking [OR=9.429 (95% CI: 1.344–66.141)], and TG ≥ 1.7 mmol/L [OR=71.834 (95% CI: 7.060–730.897)] were risk factors for T2DM in patients with HBV infection (P < 0.05). Conclusion The development of T2DM in patients with HBV infection is influenced by a combination of demographic factors (age and BMI), clinical course (duration of HBV infection), comorbid dyslipidemia, and lifestyle factors (smoking).

慢性乙型肝炎（CHB）是我国常见的传染病,随着乙型肝炎病毒（HBV）在体内持续活跃复制可进展为肝硬化甚至肝癌,严重威胁患者健康与生命,而高病毒载量CHB患者不仅进展为肝硬化、肝癌的风险和发生母婴垂直传播的风险增加,还存在抗病毒治疗病毒学应答率偏低等特点,目前对高病毒载量CHB患者的管理已引起国内外学者的关注,但尚缺乏系统的研究与阐述。本文将针对上述问题结合国内外相关文献进行综述,期望今后本领域学者对高病毒载量CHB这类特殊患者能有更深入的研究。

Chronic hepatitis B（CHB）is a common infectious disease in China．With the continuous active replication of hepatitis B virus（HBV）in the body,cirrhosis and even liver cancer can progress,seriously threatening the health and life of patients．However,CHB patients with high viral load not only have an increased risk of cirrhosis and liver cancer,mother-to-child vertical transmission,but also with a lower rate of virological response to antiviral therapy．At present,the management of CHB patients with high viral load has attracted the attention of scholars at home and abroad,but there is still a lack of systematic research and elaboration．This paper will focus on the above problems combined with relevant domestic and foreign literature review,hoping that scholars in this field can have more in-depth research on special patients with high viral load CHB in the future．

自身免疫性肝炎（AIH）是由不明原因免疫异常引起的急性或慢性肝脏炎症性疾病,不分年龄或性别,影响所有种族群体。AIH如果没有得到及时的治疗,可能会发展为肝硬化、肝衰竭,甚至导致死亡。目前一些诊断评分系统和肝活组织病理检查已成为诊断的标准,然而由于疾病表现的高度异质性,AIH诊断仍很有挑战性。大多数患者最初对一线治疗（糖皮质激素与硫唑嘌呤的联合治疗）有应答,然而,应答欠佳和因不良反应引起的不耐受也不少见,需要二线和（或）三线治疗。本文总结阐述诊断困难、一线药物治疗应答欠佳或不耐受的疑难AIH诊断和管理的最新进展,并归纳了目前国内外关于AIH治疗的新方法,为AIH的临床诊疗提供参考。

Autoimmune hepatitis（AIH）is an acute or chronic inflammatory disease of liver caused by unclear immune response that affects people from all ethnic groups irrespective of age or sex．If left untreated,AIH will lead to cirrhosis,liver failure,or death．A number of diagnostic scoring systems and histopathological examination of liver biopsies are now the standard for diagnosis．However,due to the high heterogeneity of the disease presentation,AIH diagnosing remains challenging．Most patients initially respond to first-line treatment,which is corticosteroids combined with azathioprine．However,insufficient response and intolerance due to side effects are also common,so some patients requires second-and/or third-line therapies．Here we summarized the latest progress in diagnosis and management of AIH with difficult diagnosis,poor response to first-line drug treatment or intolerance,as well as the new methods of AIH treatment worldwide,to provide reference for the clinical diagnosis and treatment of AIH．

目的 探讨慢性乙型肝炎病毒（HBV）感染对妊娠期糖尿病（GDM）孕妇的妊娠并发症、孕晚期生殖道B族链球菌（GBS）感染情况以及妊娠结局的影响。方法 选取2020年1月1日—12月31日在广州市妇女儿童医疗中心定期产检、足月、单胎妊娠的GDM孕妇共583例,其中合并HBV感染者（GDM+HBV组）48例,无合并者（GDM组）535例。比较2组的妊娠期并发症、妊娠晚期（妊娠35~37周）生殖道GBS感染情况、妊娠结局以及阴道分娩者的母儿结局。结果 与GDM组患者相比,GDM+HBV组患者出现妊娠期肝内胆汁淤积症、孕晚期生殖道GBS感染者比例较高,孕期出现胎盘早剥者比例较高,阴道分娩过程中出现产时发热、羊水粪染和新生儿入住NICU者比例均较高（均P<0.05）。结论 与无合并慢性HBV感染的GDM患者相比,合并慢性HBV感染的GDM患者在围产期的母儿风险升高。

Objective To investigate the effects of chronic hepatitis B virus（HBV）infection on pregnancy complications,group B streptococcus（GBS）infection in third trimester and pregnancy outcome in pregnant women with gestational diabetes mellitus（GDM）．Methods A retrospective study of 583 pregnant women with GDM,singleton gestation and cephalic presentation delivered at term in Guangzhou Women and Children’s Medical Center was carried out．Including 48 GDM women complicated with chronic HBV infection（GDM+HBV group）and 535 GDM women without HBV infection（GDM group）．Pregnancy complications,GBS infection in third trimester（gestation 35-37 weeks）,pregnancy outcomes,maternal and neonatal outcomes of vaginal delivery were compared between the two groups．Results GDM+HBV group had a higher proportion of intrahepatic cholestasis of pregnancy（ICP）and GBS infection in third trimester than GDM group,and a higher proportion of placental abruption during pregnancy．GDM+HBV group showed a significantly increased proportion in intrapartum fever,meconium-stained amniotic fluid and neonatal intensive care unit admission during vaginal delivery than GDM group（all P<0.05）．Conclusions GDM women with chronic HBV infection are associated with increased maternal and fetal risk during pregnancy and delivery．

目的 探讨与研究白介素-33（IL-33）、白介素-37（IL-37）、亮氨酸富集的核苷酸结合寡聚结构域-3（NLRP-3）及自然杀伤（NK）细胞/树突状细胞（DC）比值与慢性乙型肝炎（CHB）患者病情的相关性。方法 研究时间为2020年2月—2022年9月,选择在本院诊治的86例CHB患者作为肝炎组,同期选择86名体格检查健康者作为对照组。检测2组血清IL-37、IL-33、NLRP3含量,并计算NK/DC比值。对所有入选者的血清谷丙转氨酶（ALT）、谷草转氨酶（AST）、总胆红素（TBIL）含量进行检测并实施相关性分析。结果 与对照组相比,肝炎组的血清ALT、TBIL、AST有的增高趋势（P<0.05）,肝炎组的血清IL-33、IL-37、NLRP3含量更高（P<0.05）,NK/DC比值下降（P<0.05）。在肝炎组中,Pearson分析显示IL-33、IL-37、NLRP3、NK/DC比值与ALT、TBIL、AST均存在相关性（P<0.05）。在肝炎组中,ROC曲线分析显示IL-33、IL-37、NLRP3、NK/DC比值预测CHB病情的曲线下面积为0.705（95%CI：0.404~1.123）、0.690（95%CI：0.372~1.057）、0.670（95%CI：0.378~1.043）、0.685（95%CI：0.415~1.107）,联合检测预测病情的曲线下面积为0.895（95%CI：0.532~1.216）,与单独检测相比,联合检测具有更高的特异度与灵敏度。结论 CHB患者多伴随有血清IL-33、IL-37、NLRP3的高表达,并且NK/DC比值会降低,IL-33、IL-37、NLRP3及NK/DC比值与CHB患者病情存在相关性,联合检测对患者病情具有一定的预测性。

Objective To explore and study the correlation between interleukin-33(IL-33),interleukin-37(IL-37),leucine-enriched nucleotide-binding oligomeric domain(NLRP)- 3,the ratio of natural killer(NK)cells/dendritic cells(DC)and the conditions of patients with chronic hepatitis B(CHB). Methods From February 2020 to September 2022,86 patients with CHB treated in our hospital were selected as hepatitis group,and 86 healthy patients were selected as control group during the same period. The contents of IL-37,IL-33 and NLRP3 in serum of the two groups were detected,and NK/DC ratio was calculated. Serum alanine aminotransferase(ALT),aspartate aminotransferase(AST)and total bilirubin(TBIL)of all the selected subjects were detected and correlation analysis was carried out. Results Compared with the control group,the serum ALT,TBIL and AST in hepatitis group were significantly increased(P<0. 05),the contents of IL-33,IL-37 and NLRP3 were higher(P<0. 05),and the NK/DC ratio was significantly decreased(P<0. 05). In the hepatitis group,Pearson analysis showed that IL-33,IL-37,NLRP3 and NK/DC ratios were correlated with ALT,TBIL and AST(P<0. 05). In the hepatitis group,ROC curve analysis showed that the maximum areas under the curve of IL-33,IL-37,NLRP3 and NK/DC ratios were 0. 705(95%CI：0. 404-1. 123),0. 690(95%CI：0. 372-1. 057),0. 670(95%CI：0. 378-1. 043)and 0. 685(95%CI：0. 415-1. 107),and the maximum area under the curve of combined detection was 0. 895(95%CI：0. 532-1. 216). Compared with single detection,combined detection had higher specificity and sensitivity. Conclusions The patients with CHB are often accompanied by the high expression of serum IL-33,IL-37 and NLRP3,and the NK/DC ratio will be significantly reduced. IL-33,IL-37,NLRP3 and NK/DC ratio are correlated with the condition of patients with CHB,and can also predict the condition of patients.

目的 探究乙型病毒性肝炎不同状态合并2型糖尿病患者的临床特点。方法 对62例乙型肝炎病毒携带合并2型糖尿病(组1)、129例乙型病毒性肝炎合并2型糖尿病(组2)和83例乙型病毒性肝炎肝硬化合并2型糖尿病(组3)患者的临床资料进行回顾性分析。结果 各组间在性别和年龄上差异有统计学意义(χ²=11.133、P=0.004,F=7.640、P=0.001)。3组研究对象糖化血红蛋白(HbA1c)、总胆固醇(Tch)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、血清白蛋白(ALB)、总胆红素(TBIL)、直接胆红素(DBIL)、间接胆红素(IBIL)和总胆汁酸(TBA)水平差异有统计学意义(F=4.028、P=0.019,F=4.140、P=0.017,F=3.172、P=0.044,F=6.701、P=0.002,F=53.156、P<0.001,F=4.920、P=0.008,F=4.173、P=0.017,F=7.181、P=0.001,F=9.170、P<0.001)。进一步两两比较,肝炎肝硬化组HbA1c、Tch 、LDL-C、ALB水平降低,但TBIL、IBIL、TBA增高,分别与另2组比较差异有统计学意义(P<0.05);组2空腹血糖(FBG)、HDL-C水平最高,前者高于组1,后者高于组3。各组糖尿病并发症居前三的都是周围神经病变、糖尿病肾病和糖尿病视网膜病变。结论 乙型病毒性肝炎合并2型糖尿病时其不同状态间具有不同的疾病特点,主要体现在携带状态Tch、TG、LDL-C高水平,肝炎状态FBG高水平,肝炎肝硬化状态HbAlc、ALB低水平但胆红素、胆汁酸水平高,在糖尿病并发症方面均以周围神经病变、糖尿病肾病和糖尿病视网膜病变为主。

Objective To study the clinical feature of different viral hepatitis B status with type 2 diabetes. Methods A retrospective analysis was carried out on 62 hepatitis B virus carriers with type 2 diabetes (group 1),129 viral hepatitis B patients with type 2 diabetes (group 2) and 83 viral hepatitis B cirrhosis patients with type 2 diabetes (group 3). Results The differences in gender and age among the three groups were significantly different (χ²=11.133, P=0.004 and F=7.640,P=0.001). The levels of HbA1c, total cholesterol (Tch), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), serum albumin (ALB), total bilirubin(TBIL), direct bilirubin (DBIL), indirect bilirubin (IBIL)and total bile acid (TBA)in three groups were significantly different (F=4.028, P=0.019.F=4.140, P=0.017.F=3.172, P=0.044.F=6.701, P=0.002.F=53.156, P<0.001.F=4.920, P=0.008.F=4.173, P=0.017.F=7.181, P=0.001.F=9.170, P<0.001). In further pairwise comparison, the levels of HbA1c, Tch, LDL-C and ALB of group 3 decreased significantly compared with other two groups, but the levels of TBIL, IBIL and TBA increased, with significant differences.The levels of fasting blood glucose(FBG) and HDL-C in group 2 were the highest,and the FBG was significantly higher than that in group 1, while the HDL-C was significantly higher than that in group 3.In the three groups, the top three diabetic complications were peripheral neuropathy, diabetic nephropathy and diabetic retinopathy. Conclusion Different statuses of viral hepatitis B with type 2 diabetes had different disease characteristics, mainly reflected in the high levels of Tch, TG and LDL-C in the hepatitis B virus carriers, high FBG level in the viral hepatitis B patients, low levels of HbAlc and ALB but high levels of bilirubin and bile acid in the cirrhosis patients.Peripheral neuropathy, diabetic nephropathy and diabetic retinopathy were the main complications of diabetes.

目的 探讨华南地区自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征(AIH-PBC OS)临床特点,提高对该病的认识。方法 回顾性总结2010年1月—2020年1月期间收治的居住在华南地区AIH-PBC OS患者37 例,对患者的临床表现、血清学、影像学和病理学特点,伴发肝外自身免疫性疾病等情况进行分析。结果 37例AIH-PBC OS以女性(94.6%)为主,平均发病年龄(48.3±10.3)岁,确诊年龄(50.4±9.2)岁,病程(2.7±2.5)年。83.8%患者存在临床症状,以乏力纳差,身目黄染、尿黄及瘙痒最为常见。在所有患者中,诊断为慢性肝炎为45.9%,代偿性肝硬化为18.9%,失代偿性肝硬化为35.1%,合并肝外自身免疫性疾病占35.1%,以自身免疫性甲状腺疾病和干燥综合征最常见。血清谷丙转氨酶、谷草转氨酶、谷氨酰转肽酶、碱性磷酸酶、总胆红素、总胆固醇、低密度脂蛋白胆固醇水平均升高,失代偿肝硬化期患者血红蛋白和白蛋白下降(P<0.05)。近一半患者血清免疫球蛋白G、免疫球蛋白M和免疫球蛋白A水平升高,失代偿肝硬化期患者免疫球蛋白G升高最为明显(P<0.05)。自身抗体包括抗核抗体阳性率、抗线粒体抗体和(或)抗线粒体抗体M2型抗体阳性率、抗平滑肌抗体阳性率、抗核点蛋白抗体阳性率、抗核包膜蛋白抗体阳性率分别为92%、67.6%、10.8%、11.1%、13.8%。病理学提示AIH-PBC OS患者可见汇管区淋巴细胞和浆细胞浸润,肝小叶界面炎,并伴有不同程度小胆管病变,70.2%同时伴有AIH-PBC特征。肝脏影像学显示在所有患者中,29.7%存在肝硬化,18.9%存在门静脉高压,62.2%存在脾大,18.9%存在腹腔积液。结论 AIH-PBC OS同时具有AIH及PBC疾病的临床特点,病情较复杂、发病较隐蔽;同时伴有血脂代谢障碍,且容易并发肝外自身免疫性疾病。

目的 观察恩替卡韦治疗e抗原阳性慢性乙型病毒性肝炎慢加急性肝衰竭(CHB-ACLF)的近期疗效及安全性。方法 选择e抗原阳性CHB-ACLF患者60例,均为我院2016年6月—2017年6月收诊,随机分为各30例的治疗组(采用恩替卡韦治疗)与对照组(采用拉米夫定片治疗),连续用药6个月后,对比疗效及安全性差异。结果 治疗6个月后,治疗组的ALB、PTA水平高于对照组,TBIL、ALT水平低于对照组,MELD评分与HBV-DNA定量少于对照组(P＜0.05);治疗后6个月,两组的HBV-DNA转阴率均高于治疗后1、3个月,且治疗组高于对照组(P＜0.05);治疗期间,治疗组患者死亡4例(13.33%),对照组患者死亡6例(20.00%),两组的死亡率比较无统计学意义(P＞0.05)。结论 恩替卡韦分散片是一种安全、有效的抗e抗原阳性CHB-ACLF药物,能有效抑制病毒复制和改善肝功能,促进患者预后转归。

目的 分析妊娠期慢性乙型肝炎病毒携带者病毒载量与孕妇肝功能、妊娠并发症的相关性。方法 将本院2015年1月—12月间在本院住院并于本院分娩的携带慢性乙型肝炎病毒(HBV)的86例孕妇作为本次研究对象,于住院期间分娩前测定孕妇HBV脱氧核糖核酸(HBV-DNA)定量,依据HBV-DNA定量测定结果将全部患者分为阴性组与阳性组,分别对比2组患者的临床资料、肝功能、妊娠并发症发生率及母婴结局;分析HBV-DNA载量与孕妇妊娠期肝功能及妊娠并发症的相关性。结果 2组孕妇的年龄、BMI、孕次与产次均无差异,P>0.05;阴性组患者妊娠期肝功能指标优于阳性组,P<0.01。阴性组中羊水量异常(偏多或偏少)发生率高于阳性组,P<0.05;其他妊娠期并发症发生率2组均未见差异,P>0.05。2组母婴结局均未见统计学差异,P>0.05。HBV载量与ALT肝功能指标均呈正相关,0<r<1,说明HBV-DNA越高则ALT越高,孕妇的肝功能越差。HBV载量与并发症发生间基本不相关,|r|<0.3,P>0.05。结论 慢性乙型肝炎病毒携带者妊娠期时随着病毒载量的升高,孕妇的肝功能有所下降仍可维持在正常标准,但与妊娠并发症的发生无相关性;提示对HBV-DNA阳性的孕妇给予密切监护,通过临床常规对症治疗能够保证母婴安全。

Objective To analyze the correlation between viral load of chronic hepatitis B virus infection and liver function and pregnancy complications. Methods We selected 86 cases of pregnant women with chronic hepatitis B virus(HBV)in our hospital from January 2015 to December 2015 as the research objects, and then during the hospitalization to test the quality of the HBV deoxyribonucleic acid (HBV-DNA)for them before delivery. According to the HBV-DNA quantitative results, all patients were divided into low dosage group and high dosage group, and then the clinical data, liver function, the incidence rate of pregnancy complications and the outcomes of the two groups were compared; at last we analyzed the correlation among the HBV-DNA load, liver function of pregnant women during pregnancy and pregnancy complications. Results There was no difference between the two groups of pregnant women in the age, BMI, pregnancy and birth time, P>0.05; the low dose group was better than the high dose group in the liver function index during the pregnancy, P<0.01. The incidence of abnormal amniotic fluid volume (more or less) in the low dose group was higher than that in the high dose group, P<0.05; there was no significant difference between the two groups in the incidence of other complications, P>0.05. There was no statistical difference between the two groups in maternal and neonatal outcomes, P>0.05. The HBV load was positively correlated with the two liver function indexes ALT, 0<r<1, indicating that the higher the HBV-DNA, the higher theALT, the worse the liver function of the pregnant women. There was no correlation between HBV load and complications, |r|<0.3, P>0.05. Conclusion Chronic hepatitis B virus carriers during pregnancy with increasing viral load, liver function of pregnant women declined to maintain in normal level, but not associated with pregnancy complications; that of HBV-DNA positive pregnant women given close monitoring of disease through clinical routine treatment can ensure the safety of mother and child.

       戊型肝炎病毒（HEV）是导致急性肝炎的重要病原体，部分HEV感染者可进展为肝衰竭，此外，慢性感染和肝外表现可也在HEV感染者中发生。全球每年感染HEV的患者数达2000万，其中330万例患者有肝炎相关的临床症状，年死亡例数约为4.4万（2015年数据）。在我国，HEV以散发流行为主。近年来由于对其研究的重视，HEV病原学、流行病学、临床诊疗和预防取得较大的进展，文章拟对目前HEV防治热点以及新进展进行总结和分析。

       Hepatitis E virus（HEV）is an important pathogen that causes acute hepatitis．Some HEV-infected individuals 

may progress to liver failure．In addition，chronic infection（including liver fibrosis and cirrhosis）and extrahepatic manifestations can also occur in HEV infection．Worldwide，there are 20 million cases of HEV infection each year，with  3.3 million cases presenting clinical symptoms related to hepatitis，and an annual death toll of approximately 44，000（data from 2015）．In China，HEV mainly present as sporadic outbreaks．In recent years，there has been significant progress in the pathogenesis，epidemiology，clinical diagnosis and treatment，and prevention of HEV．This review aims to summarize and analyze the current hotspots and new developments in the prevention and treatment of HEV．